Fig. 2

Identifications of transcriptomic profiles of lung FB samples from patients with IPF and healthy donors (HD). A Principal component analysis on IPF/HD-derived FB samples from the apex (n = 12) and basal lung sites (n = 12, GSE185492). B Volcano plot displaying identified DEGs in IPF-FB compared with HD-FB from the basal lung site (GSE185492) by log2 foldchange (x-axis) and adjust P-value (y-axis). Blue dots represent DEGs significantly down-regulated; red dots represent DEGs significantly upregulated; grey dots represent genes not significantly regulated. C Principal component analysis on IPF/HD-derived FB samples from the upper lobe lung site (n = 9, GSE180415). D Volcano plot displaying identified DEGs in IPF-FB compared with HD-FB from the upper lobe lung site (GSE180415) by log2 foldchange (x-axis) and adjust P-value (y-axis). Blue dots represent DEGs significantly down-regulated; red dots represent DEGs significantly upregulated; grey dots represent genes not significantly regulated. E Venn diagrams depicting the number of DEGs specifically or mutually regulated in IPF-FB samples from different lung anatomical sites. F Enriched analysis by EGO using DEGs identified in IPF-FB samples from upper lobe lung and basal lung sites. G, H RNA-seq expression normalized value (fragments per kilobase of exon model per million mapped fragments, FPKM) for transcripts encode for genes related to response to TGF-β1 stimulus and muscle tissue development in each RNA-seq dataset